Quest Diagnostics is a leading global provider of diagnostic information services, specializing in laboratory testing and related services. The company offers a comprehensive range of medical testing, including routine blood work, genetic testing, and specialized diagnostic imaging, aimed at helping healthcare providers make informed decisions about patient care. With a vast network of laboratories and patient service centers, Quest Diagnostics plays a critical role in the healthcare ecosystem by delivering accurate and timely results, contributing to enhanced patient outcomes and supporting public health initiatives. Through their innovative technologies and dedication to quality, the company strives to advance the practice of medicine and improve overall health management. Read More
Let's delve into the developments on the US markets one hour before the close of the markets on Tuesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Gold prices suffered a sharp correction on Tuesday as investors locked in profits following this year's explosive rally, while optimism across earnings kept industrial stocks powering higher and pushed the Dow Jones to fresh record highs.
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Tuesday to find the gap up and gap down stocks in today's session.
Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) reported revenue ahead of Wall Street’s expectations in Q3 CY2025, with sales up 13.2% year on year to $2.82 billion. The company’s full-year revenue guidance of $10.98 billion at the midpoint came in 1% above analysts’ estimates. Its non-GAAP profit of $2.60 per share was 3.9% above analysts’ consensus estimates.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
bioAffinity Technologies, Inc. (NASDAQ: BIAF) has emerged as a standout performer in the financial markets today, September 26, 2025, with its stock experiencing a dramatic surge. The significant uptick, which saw shares climb by over 52% in premarket trading and reach highs of 79% and 60.71% during Friday's session,
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced a broad strategic collaboration to make Guardant’s Shield™ blood-based screening test available to physicians and patients served by Quest in the United States.
WHOOP, the human performance company, today announced that Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, will be the U.S. lab provider for WHOOP Advanced Labs, a new WHOOP feature that provides laboratory insights supporting health and performance. The offering will provide the option to purchase Quest’s clinical laboratory testing, schedule an appointment for testing, and receive test results within the WHOOP app. WHOOP Advanced Labs is scheduled to launch this fall.
Join us as we analyze Quest Diagnostics and uncover whether this lab giant is a smart investment choice for the future. With insights from industry experts, you won't want to miss this evaluation!
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how testing & diagnostics services stocks fared in Q2, starting with Quest (NYSE:DGX).
